Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase NA 1Phase 1/2 1

Status

Unknown 4Recruiting 2

Sponsor Class

OTHER 342INDUSTRY 92NIH 21NETWORK 9OTHER_GOV 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 5Plasma cell 2Other solid neoplasm 2Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Burkitt Lymphoma 3Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 12Rituximab 9fludarabine 6Prednisone 5Vinorelbine 4Vincristine 4Epirubicin 4zanubrutinib 3Nivolumab 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3Drug Therapy 3pegylated granulocyte colony-stimulating factor 2fludarabine phosphate 2Thiotepa 2Metformin 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Doxorubicin 2Cytarabine 2Bortezomib 2treosulfan 1plerixafor 1pegfilgrastim 1parsaclisib 1obinutuzumab 1nilotinib 1liposomal doxorubicin 1ivarmacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER_GOV × fludarabine × Lymphoid × Clear all
NCT06160362 2023-12-07

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Henan Cancer Hospital

Phase NA Unknown
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT06056752 2023-10-24

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Anhui Provincial Hospital

Phase 1 Recruiting
10 enrolled
Lymphoid

Burkitt Lymphoma

NCT05528887 2022-09-06

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

The Affiliated People's Hospital of Ningbo University

Phase 1 Recruiting
10 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT02924753 2017-12-29

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Henan Cancer Hospital

Phase 1 Unknown
20 enrolled
Lymphoid

Burkitt Lymphoma

NCT03263208 2017-10-20

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Henan Cancer Hospital

Phase 1/2 Unknown
20 enrolled
Lymphoid

Burkitt Lymphoma

NCT03101709 2017-04-05

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Henan Cancer Hospital

Phase 1 Unknown
30 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡